Keyphrases
Alfacalcidol
60%
Secondary Hyperparathyroidism
60%
Hemodialysis Patients
56%
Hemodialysis
55%
Paricalcitol
42%
Hyperphosphatemia
35%
Magnesium Supplementation
30%
Dialysis
25%
Inflammatory Markers
22%
Vascular Calcification
22%
Parathyroid Hormone Levels
21%
Chronic Kidney Disease
19%
Vitamin D Analogs
19%
End-stage Renal Disease
18%
Mg Magnesium
18%
High Dose
18%
Intact Parathyroid Hormone (iPTH)
18%
Randomized Crossover Trial
17%
Chronic Hemodialysis
16%
Peripheral Blood Pressure
15%
Healthcare Professionals
15%
Dialysate Magnesium
15%
T 50
15%
Antibiotic Treatment
15%
Fibroblast Growth Factor 23 (FGF23)
15%
Central Blood Pressure
15%
Cholecalciferol
15%
Randomized Clinical Trial
15%
Arterial Stiffness
15%
Low Calcium
15%
Catheter-related
15%
Randomized Crossover Study
15%
Decision Support Tool
15%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
15%
Sepsis
15%
Healthy Individuals
15%
BIOCHEMICAL MARKERS OF BONE TURNOVER
15%
Serum Calcification Propensity
15%
Chronic Obstructive Pulmonary Disease
15%
Randomized Controlled Trial
15%
YKL-40
15%
Pharmacology, Toxicology and Pharmaceutical Science
Hemodialysis
100%
Alfacalcidol
61%
Secondary Hyperparathyroidism
60%
Paricalcitol
42%
Hyperphosphatemia
35%
End Stage Renal Disease
33%
Controlled Clinical Trial
30%
Parathyroid Hormone
24%
Chronic Kidney Failure
19%
Vitamin D Analog
19%
Bloodstream Infection
15%
Brain Natriuretic Peptide
15%
Dialysis Fluid
15%
Placebo
15%
Fibroblast Growth Factor 23
15%
Medicine and Dentistry
Hemodialysis
68%
Magnesium
30%
Secondary Hyperparathyroidism
30%
Parathyroid Hormone
24%
Hyperphosphatemia
22%
Dialysis Catheter
22%
Bloodstream Infection
22%
End Stage Renal Disease
21%
Isotopes of Calcium
21%
Chronic Kidney Disease
18%
Randomized Clinical Trial
18%
Antibiotic Therapy
15%
Dialysis Fluid
15%
Supplementation
15%
Blood Vessel Calcification
15%
Sepsis
15%
Controlled Clinical Trial
15%
Infection
15%
Escherichia
15%
